Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bismuth subsalicylate

PreclinicalSmall molecule

1

Indications

8

Total Trials

0

Active Trials

0

Competitors

Clinical

Trials by Indication[1]

Diarrhea2 trials

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

Terminated·CCenters for Disease Control and Prevention·Phase 3·NCT03535272·482 enrolled

Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan

Completed·CCenters for Disease Control and Prevention·N/A·NCT02047162·400 enrolled

Gut Microbiome1 trial

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05930197·34 enrolled

Helicobacter Pylori Infection1 trial

Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01742429·200 enrolled

Colitis1 trial

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Withdrawn·BBassett Healthcare·Phase 4·NCT03592082

MALT lymphoma1 trial

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002682·5 enrolled

2 more indications

Helicobacter Pylori Eradication1 trial

THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY

Completed·FFatih Sultan Mehmet Training and Research Hospital·Phase 4·NCT03757650·3 enrolled

Gastrointestinal1 trial

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Completed· Biogen logo

Biogen·Phase 1·NCT01915901·175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Bismuth subsalicylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bismuth subsalicylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bismuth subsalicylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Biogen

Related News